Navigation Links
Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
Date:6/27/2008

s and GSK established a broad alliance to discover, develop, and commercialize novel therapeutics in the areas of vascular biology, inflammatory disease, and oncology. Under the agreement, Exelixis was required to deliver to GSK a number of small molecule compounds that met agreed-upon proof-of-concept criteria, and GSK had the option to select up to two of these compounds for further development, and worldwide commercialization.

In January 2005, the GSK agreement was amended to focus on 12 specific programs: XL647, XL999, XL784, XL880, XL820, XL844, XL184, XL281, XL418, XL228 and two earlier-stage programs, from which GSK had the right to make its development elections. Exelixis retains rights to collaboration compounds not selected by GSK, subject to payment to GSK of a low, single-digit royalty on certain "Refused Candidates" that GSK elects not to choose with its development election which Exelixis thereafter successfully commercializes. Under the amended agreement, GSK may pay selection milestones, additional development-related milestones, and double-digit royalties on product sales with respect to selected compounds. Exelixis has certain co-promotion rights in North America for compounds selected by GSK for further development.

In August 2007, GSK requested to initiate its review of XL880 before the compound reached proof-of-concept in phase 2 trials. Exelixis agreed to this request and submitted the data report to GSK in September 2007. In December 2007, GSK exercised its development option for XL880, triggering a $35 million selection milestone, which offset a milestone payment previously paid by GSK. GSK has the right to select one additional compound for development and commercialization from remaining programs in clinical development (XL184, XL281, XL228, XL820, and XL844) and if its election decision is made for a compound submitted during the development term, Exelixis would be owed a $55 million selection milestone, with the milestone cr
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 Space is ... exploration of space requires astronauts to maintain consistently high ... success, and prevent potential errors and accidents. Despite the ... known about how cognition is affected by prolonged spaceflight, ... Now, Penn Medicine researchers are poised to help ...
(Date:11/26/2014)... The ETC (Emerging Technology Centers) ... announced today that applications for AccelerateBaltimore™ (AB) 2015 ... you have a big idea?,” asked ETC’s President ... about it. AccelerateBaltimore helps you and your big ... 13 weeks.” Interested game changers with “big ...
(Date:11/26/2014)... November 25, 2014 SonaCare Medical, ... Ultrasound (HIFU) devices, recently participated in the American ... Mass 360° .” Key opinion leaders in urology ... related to small renal masses while attendees had ... ablative technologies in hands-on labs. Attendees at the ...
(Date:11/26/2014)... November 25, 2014 The Pittcon marketing ... official conference and exposition mobile app, ... download in the App Store for iOS and Android ... resource tool before, during and after the event. It ... on exhibiting companies, technical sessions, Conferee Networking sessions and ...
Breaking Biology Technology:Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Pittcon Releases 2015 Mobile App 2
... June 23 Replidyne, Inc.,(Nasdaq: RDYN ) today ... with Asubio Pharma Co., Ltd. for faropenem medoxomil (faropenem).,In ... it has,terminated its supply agreement with Asubio Pharma Co., ... These decisions were made as a,result of the Company ...
... Web-based programs give sponsors easy-to-use tools to store, mine ... transfer knowledge base to ensure enrollment success, ... recruitment technology leader, announced the release of a new,product, ... support in-house recruitment capabilities for clinical,trial sponsors. The goal ...
... Ariz., June 23 MedPredict has published ... insight for pharma and,biotech companies hoping to ... The report, entitled "Thought Leader Insight & ... with a panel of,specialists in anesthesiology, psychiatry, ...
Cached Biology Technology:Replidyne Terminates Faropenem Agreements 2Replidyne Terminates Faropenem Agreements 3TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 2TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 3TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 4In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict 2
(Date:11/4/2014)... --   3D scanner developer ... Fuel3D , a developer of 3D scanning solutions, today ... million (£4 million). This funding builds on the company,s initial ... paves the way for the commercial launch of the company,s ... was led by Chimera Partners and will be used to ...
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
(Date:11/3/2014)... of Colorado Cancer Center study published in ... Sciences describes the activity of a recently discovered ... or IL-37. It has been known to limit inflammation ... adaptive immune system: IL-37 inhibits the ability of the ... "Knowing this mechanism that underlies IL-37,s effect on the ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... 2009)A minimally invasive interventional radiology treatmentthat safely and ... herniated diskswill become standard in the United States ... the Society of Interventional Radiology,s 34th Annual Scientific ... examined just how ozone relieves the pain associated ...
... once a week displayed higher cognitive skills at the age of ... a study of nearly 4,000 teenagers published in the March issue ... a week was enough to increase combined, verbal and visuospatial intelligence ... more than once a week increased them by just under 11 ...
... strokes has taken a significant step forward today (09 ... brain tissue in rats. The team of scientists ... Council (BBSRC) and led by Dr Mike Modo of ... work, carried out at the Institute of Psychiatry and ...
Cached Biology News:Oh, my aching back: Give me a shot of ozone 2Oh, my aching back: Give me a shot of ozone 3Teenage boys who eat fish at least once a week achieve higher intelligence scores 2Teenage boys who eat fish at least once a week achieve higher intelligence scores 3Stem cells replace stroke-damaged tissue in rats 2
GLP-compliant, CLIA-certified DNA sequencing service. ASQ and SQA certified quality assurance staff. Auditors welcome....
Sequencing and primer design rolled into one. Just give us your clone and a reference sequence, and we'll do the rest. Single-strand or double-strand coverage. Guaranteed results....
... to human XAB2 (amino terminus) XAB2 ... its interaction with XPA. Immunoprecipitation experiments have ... interacts with the transcription-coupled repair-specific proteins CSA ... polymerase II. Microinjection experiments with XAB2 antibodies ...
... using advanced automated high throughput microplate processing equipment that dispenses ... accommodate virtually any lot size of the following formats (with ... 8 and 12 well strips, ... 384 well microplate, 1536 ...
Biology Products: